Cardio Diagnostics Inc. (CDIO)
0.60
0.03 (5.15%)
At close: Jan 15, 2025, 10:55 AM
Company Description
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Cardio Diagnostics Inc.
| Country | United States |
| IPO Date | Jan 14, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Meeshanthini V. Dogan Ph.D. |
Contact Details
Address: 400 N Aberdeen St Chicago, Illinois United States | |
| Website | https://cardiodiagnosticsinc.com |
Stock Details
| Ticker Symbol | CDIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870144 |
| CUSIP Number | 14159C103 |
| ISIN Number | US14159C1036 |
| Employer ID | 87-0925574 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Meeshanthini V. Dogan Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Financial Officer |
| Timur Dogan Ph.D. | Chief Technology Officer |
| Dr. Robert A. Philibert M.D., Ph.D. | Co-Founder, Chief Medical Officer & Director |
| Khullani Abdullahi J.D. | Vice President of Revenue & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 8-K | Current Report |
| Dec 03, 2024 | 424B3 | Filing |
| Nov 22, 2024 | S-1 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 10, 2024 | 4 | Filing |
| Oct 10, 2024 | 4 | Filing |
| Oct 10, 2024 | 4 | Filing |
| Oct 10, 2024 | 4 | Filing |
| Oct 09, 2024 | 4/A | [Amend] Filing |